Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 4 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.

Angiogenic factors hold promise in triage of women with suspected pre-eclampsia

04 Sep 2019

Measuring the ratio of the soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) improves the accuracy of identifying pre-eclampsia without changing admission rates, according to the results of a trial.

The trial assessed the utility of sFlt-1/PlGF ratio in 370 women presenting with suspected pre-eclampsia who were then randomly allocated to groups that did (n=186) and did not (n=184) reveal the result of the test to clinicians.  

Researchers used a ratio cutoff of 38 to define low (≤38) and elevated risk (>38) of developing pre-eclampsia in the subsequent week. The primary outcome was hospitalization within 24 hours of the test, while secondary outcomes included development of pre-eclampsia and other adverse maternal–foetal outcomes.

Pre-eclampsia occurred in 85 women (23 percent) overall. The number of admissions did not significantly differ between the reveal and nonreveal groups (48 vs 60; p=0.192). All women who developed the pregnancy disorder in the reveal group were admitted within 7 days, as compared with 83 percent of those in the nonreveal group (p=0.038).

For predicting the development of pre-eclampsia within 7 days, the sFlt-1/PlGF ratio test yielded a sensitivity of 100 percent (95 percent CI, 85.8–100) and a negative predictive value (NPV) of 100 percent (97.1–100). In comparison, clinical practice alone achieved 83.3 percent (58.6–96.4) sensitivity and 97.8 percent (93.7–99.5) NPV.

The researchers also noted a trend towards reduced time to diagnosis of the pregnancy disorder when using the test. Taken together, the findings suggest that he sFlt-1/PlGF ratio test allows the correct triage and hospitalization of women with suspected pre-eclampsia without changing admission rates.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 4 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.